Area of research
Neurology · Physiology
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological diseases and metabolism, Amyotrophic Lateral Sclerosis Research, and Alzheimer's disease research and treatments.
Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing
Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction
TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia
Genome sequence analyses identify novel risk loci for multiple system atrophy
Embracing Monogenic Parkinson's Disease: The <scp>MJFF</scp> Global Genetic <scp>PD</scp> Cohort
Basal activity of PINK1 and PRKN in cell models and rodent brain
Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges
Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders
ASLPrep: a platform for processing of arterial spin labeled MRI and quantification of regional brain perfusion
Common Variants Near <scp>ZIC1</scp> and <scp>ZIC4</scp> in Autopsy‐Confirmed Multiple System Atrophy
Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples
Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Genomewide Association Studies of <scp> <i>LRRK2</i> </scp> Modifiers of Parkinson's Disease
Neuroimaging phenotypes of <i>CSF1R</i>‐related leukoencephalopathy: Systematic review, meta‐analysis, and imaging recommendations
Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank
Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3
Utility of the global CDR<sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases
Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy
Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples
Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort
Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With <i>MAPT</i>, <i>GRN</i>, and <i>C9orf72</i> Pathogenic Variants
Clinical and pathologic features of cognitive-predominant corticobasal degeneration
Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study
Crohn’s and Parkinson’s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity